NCT06982131Active, not recruitingPhase 1
A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 May 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 24 Feb 2025
- Start date
- 8 May 2025
- Lead sponsor
- F. Hoffmann-La Roche AG
- Diseases
- Obesity
- EU CT number
- 2024-519277-18-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharma Bio-Research Group Coordinator of this site? Confirm its status | Groningen | Netherlands | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.